Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Lancet Respiratory Medicine

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S2213-2600(13)70234-0PMID 24503266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The future of antibiotics

  2014cited by this paper
• Tuberculosis vaccine trials.

  2013cited by this paper
• Differential cellular recognition pattern to M. tuberculosis targets defined by IFN-γ and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras

  2013cited by this paper
• The future of antibiotics and resistance.

  2013cited by this paper
• Mesenchymal stem cells and the lung

  2013cited by this paper
• Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells

  2013cited by this paper
• Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine.

  2013cited by this paper
• Analysis of Host Responses to Mycobacterium tuberculosis Antigens in a Multi-Site Study of Subjects with Different TB and HIV Infection States in Sub-Saharan Africa

  2013cited by this paper
• AUTOLOGOUS MESENCHYMAL STEM CELLS FOR THE TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: AN OPEN–LABEL PHASE 2A PROOF–OF–CONCEPT STUDY

  2013cited by this paper
• Treatment with mesenchymal stromal cells is a risk factor for pneumonia‐related death after allogeneic hematopoietic stem cell transplantation

  2012cited by this paper
• Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation.

  2012cited by this paper
• Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

  2012cited by this paper
• Immune Responses to ESAT-6 and CFP-10 by FASCIA and Multiplex Technology for Diagnosis of M. tuberculosis Infection; IP-10 Is a Promising Marker

  2012cited by this paper
• The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition.

  2012cited by this paper
• Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials

  2012cited by this paper
• Tuberculosis and HIV Co-Infection

  2012cited by this paper
• Emerging roles for multipotent, bone marrow-derived stromal cells in host defense.

  2012cited by this paper
• Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.

  2012cited by this paper
• Mitochondrial transfer from bone-marrow–derived stromal cells to pulmonary alveoli protects against acute lung injury

  2012cited by this paper
• Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia.

  2012cited by this paper
• Tuberculosis and HIV Co-Infection

  2012cited by this paper
• Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus

  2012cited by this paper
• Decreased IL-7 Signaling in T Cells From Patients With PTLD After Allogeneic HSCT

  2011cited by this paper
• Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk

  2011cited by this paper
• HIV-1 infection alters CD4+ memory T-cell phenotype at the site of disease in extrapulmonary tuberculosis

  2011cited by this paper
• Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease

  2011cited by this paper
• Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase

  2011cited by this paper
• Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection.

  2011cited by this paper
• Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review.

  2011cited by this paper
• Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease

  2011cited by this paper
• Immunological biomarkers of tuberculosis

  2011cited by this paper
• Mesenchymal and haematopoietic stem cells form a unique bone marrow niche

  2010cited by this paper
• High content cellular immune profiling reveals differences between rhesus monkeys and men

  2010cited by this paper
• Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis.

  2010cited by this paper
• Understanding Latent Tuberculosis: A Moving Target

  2010cited by this paper
• A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis

  2010cited by this paper
• Antibacterial Effect of Human Mesenchymal Stem Cells Is Mediated in Part from Secretion of the Antimicrobial Peptide LL‐37

  2010cited by this paper
• A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype

  2010cited by this paper
• Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

  2010cited by this paper
• Therapeutic potential of mesenchymal stem cells for severe acute lung injury.

  2010cited by this paper
• Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis

  2010cited by this paper
• WHO global tuberculosis control report 2010. Summary.

  2010cited by this paper
• Identification of growth and attachment factors for the serum-free isolation and expansion of human mesenchymal stromal cells.

  2010cited by this paper
• Cytotoxic therapy for severe swine flu A/H1N1.

  2010cited by this paper
• Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis

  2009cited by this paper
• Interleukin-7 receptor signaling is deficient in CD4+ T cells from HIV-infected persons and is inversely associated with aging.

  2009cited by this paper
• Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors

  2009cited by this paper
• Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations

  2008cited by this paper
• Comprehensive treatment of extensively drug-resistant tuberculosis.

  2008cited by this paper
• A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study.

  2008cited by this paper
• Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats.

  2008cited by this paper
• rBCG Induces Strong Antigen-Specific T Cell Responses in Rhesus Macaques in a Prime-Boost Setting with an Adenovirus 35 Tuberculosis Vaccine Vector

  2008cited by this paper
• A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study.

  2008cited by this paper
• Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin-Induced Acute Lung Injury in Mice1

  2007cited by this paper
• ESR or CRP? A comparison of their clinical utility

  2007cited by this paper
• Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell‐therapy approaches: Further insights in the search for a fetal calf serum substitute

  2007cited by this paper
• Reduced numbers of IL‐7 receptor (CD127) expressing immune cells and IL‐7‐signaling defects in peripheral blood from patients with breast cancer

  2007cited by this paper
• Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cells

  2007cited by this paper
• Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM.

  2006cited by this paper
• Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

  2006cited by this paper
• Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

  2006cited by this paper
• Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.

  2006cited by this paper
• Mitochondrial transfer between cells can rescue aerobic respiration

  2006cited by this paper
• Cytokine detection by multiplex technology useful for assessing antigen specific cytokine profiles and kinetics in whole blood cultured up to seven days.

  2006cited by this paper
• Trends in tuberculosis--United States, 2005.

  2006cited by this paper
• Evaluation of MGIT 960-Based Antimicrobial Testing and Determination of Critical Concentrations of First- and Second-Line Antimicrobial Drugs with Drug-Resistant Clinical Strains of Mycobacterium tuberculosis

  2006cited by this paper
• Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials

  2006cited by this paper
• In Vitro Expansion of Human Mesenchymal Stem Cells: Choice of Serum Is a Determinant of Cell Proliferation, Differentiation, Gene Expression, and Transcriptome Stability

  2005cited by this paper
• Human bronchial fibroblasts exhibit a mesenchymal stem cell phenotype and multilineage differentiating potentialities

  2005cited by this paper
• Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

  2005cited by this paper
• Tilting at windmills

  2005cited by this paper
• Autologous mesenchymal stem cell transplantation in stroke patients

  2005cited by this paper
• Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy.

  2004cited by this paper
• Mycobacterium tuberculosis Pathogenesis and Molecular Determinants of Virulence

  2003cited by this paper
• Development and evaluation of a flow-cytometric assay of specific cell-mediated immune response in activated whole blood for the detection of cell-mediated immunity against varicella-zoster virus.

  2003cited by this paper
• Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects

  2003cited by this paper
• Immunotherapy for tuberculosis: wave of the future or tilting at windmills?

  2003cited by this paper
• Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone

  2002cited by this paper
• Mesenchymal Stem Cells

  2002cited by this paper
• Reduced T‐cell receptor CD3ζ‐chain protein and sustained CD3ε expression at the site of mycobacterial infection

  2001cited by this paper
• Reduced T-cell receptor CD3zeta-chain protein and sustained CD3epsilon expression at the site of mycobacterial infection.

  2001cited by this paper
• Increased levels of circulating interleukin-18 in patients with advanced tuberculosis.

  2000cited by this paper
• IL-2 Unresponsiveness in Anergic CD4+ T Cells Is Due to Defective Signaling Through the Common γ-Chain of the IL-2 Receptor1

  2000cited by this paper
• Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells.

  2000cited by this paper
• Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta

  1999cited by this paper
• Epithelial/mesenchymal interactions and branching morphogenesis of the lung.

  1998cited by this paper
• Monocyte deactivation in septic patients: restoration by IFN-gamma treatment.

  1997cited by this paper
• Monocyte deactivation in septic patients: Restoration by IFN-γ treatment

  1997cited by this paper
• rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo.

  1997cited by this paper
• Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.

  1996cited by this paper
• Recognition of Human Renal Cell Carcinoma and Melanoma by HLA‐A2‐Restricted Cytotoxic T Lymphocytes is Mediated by Shared Peptide Epitopes and Up‐Regulated by Interferon‐γ

  1996cited by this paper
• Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes

  1995cited by this paper
• Prednisone as adjunctive therapy in the management of pulmonary tuberculosis. Report of 12 cases and review of the literature.

  1995cited by this paper
• Mesenchymal Stem Cells

  1991cited by this paper
• Tilting at windmills

  1977cited by this paper
• THE DEVELOPMENT OF FIBROBLAST COLONIES IN MONOLAYER CULTURES OF GUINEA‐PIG BONE MARROW AND SPLEEN CELLS

  1970cited by this paper
• Treatment of

  year unknowncited by this paper

• Mucosal-associated invariant T-cells in pulmonary pathophysiology

  2025cites this paper
• Antimicrobial peptide PK34 modification enhances the antibacterial and anti-inflammatory effects of bone-derived mesenchymal stem cells in Mycobacterium tuberculosis infection

  2025cites this paper
• Immunotherapy for tuberculosis: current strategies and future directions

  2025cites this paper
• Host-directed immunotherapy to enhance treatment of Mycobacterium tuberculosis infection.

  2025cites this paper
• Comprehensive review and reflective evaluation of cell therapies for tuberculosis

  2025cites this paper
• The Role of Mesenchymal Stem Cells in Modulating Adaptive Immune Responses in Multiple Sclerosis

  2024cites this paper
• The immunomodulatory effects of Mesenchymal stem cells on THP-1-derived macrophages against Mycobacterium tuberculosis H37Ra infection.

  2024cites this paper
• Enhanced Autophagy and Cholesterol Efflux in Mouse Mesenchymal Stem Cells Infected with H37Rv Compared to H37Ra.

  2024cites this paper
• Human mesenchymal stromal cells inhibit Mycobacterium avium replication in clinically relevant models of lung infection

  2024cites this paper
• The effect of mesenchymal stem cell conditioned medium incorporated within chitosan nanostructure in clearance of common gastroenteritis bacteria in-vitro and in-vivo

  2024cites this paper
• Comparison of Autografts and Biodegradable 3D-Printed Composite Scaffolds with Osteoconductive Properties for Tissue Regeneration in Bone Tuberculosis

  2023cites this paper
• Revisiting the role of mesenchymal stem cells in tuberculosis and other infectious diseases

  2023cites this paper
• The immune response in tubercular uveitis and its implications for treatment: From anti-tubercular treatment to host-directed therapies.

  2023cites this paper
• Enhancement strategies for mesenchymal stem cells and related therapies

  2022cites this paper
• Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases

  2022cites this paper
• Review of the Published Literature Confirms the Safety of Intravenous Infusion of Mesenchymal Stem Cells.

  2022cites this paper
• Mesenchymal-Stem-Cell-Based Strategies for Retinal Diseases

  2022cites this paper
• Alternatives to Antibiotics against Mycobacterium abscessus

  2022cites this paper
• Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases: From Basic Research to Clinical Practice

  2022cites this paper
• Mesenchymal stromal cells application for experimental genital tuberculosis combination therapy

  2022cites this paper
• Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment

  2021cites this paper
• Evaluation of the Biodistribution of Mesenchymal Stem Cells in a Pre-clinical Renal Tuberculosis Model by Non-linear Magnetic Response Measurements

  2021cites this paper
• Challenges and advances in clinical applications of mesenchymal stromal cells

  2021cites this paper
• The Research Progress in Immunotherapy of Tuberculosis

  2021cites this paper
• Mesenchymal Stromal Cells: an Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases

  2021influential citation
• Is Mycobacterium tuberculosis carcinogenic to humans?

  2021cites this paper
• Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities

  2021cites this paper
• Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review

  2021cites this paper
• Novel treatments in multidrug-resistant tuberculosis.

  2021cites this paper
• Application of 3D bioprinting in the prevention and the therapy for human diseases

  2021cites this paper
• Current approach of stem cell medicine in drug-resistant tuberculosis

  2021cites this paper
• Mesenchymal Stem Cells Adaptively Respond to Environmental Cues Thereby Improving Granulation Tissue Formation and Wound Healing

  2020cites this paper
• Host -directed Therapy: A New Arsenal to Come.

  2020cites this paper
• COVID-19 and tuberculosis-threats and opportunities.

  2020cites this paper
• The Rising Role of Mesenchymal Stem Cells in the Treatment of Various Infectious Complications

  2020cites this paper
• Recent advancement and future perspective for the treatment of multidrug-resistant tuberculosis

  2020cites this paper
• In vitro Effects of Mesenchymal Stem Cells and Their Niches in The Inhibition of M. tuberculosis Growth

  2020cites this paper
• Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?

  2020cites this paper
• Revisiting Host-Directed Adjunct Therapies in Tuberculosis

  2020cites this paper
• The changing treatment landscape for MDR/XDR-TB - Can current clinical trials revolutionise and inform a brave new world?

  2019cites this paper
• Clinical Aspects and Principles of Management of Tuberculosis

  2019cites this paper
• Clinical Application of Stem/Stromal Cells in COPD

  2019cites this paper
• Interactions of Mycobacterium tuberculosis with Human Mesenchymal Stem Cells

  2019cites this paper
• Study on drug resistance and Mycobacterium tuberculosis L-form monitoring in diabetic patients with pulmonary tuberculosis

  2019cites this paper
• Discovery of Common Putative Drug Targets and Vaccine Candidates for Mycobacterium tuberculosis sp.

  2019cites this paper
• Urogenital tuberculosis — epidemiology, pathogenesis and clinical features

  2019cites this paper
• The Manufacture of GMP-Grade Bone Marrow Stromal Cells with Validated In Vivo Bone-Forming Potential in an Orthopedic Clinical Center in Brazil

  2019cites this paper
• Single‐Use Bioreactors for Manufacturing of Immune Cell Therapeutics

  2019cites this paper
• Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future.

  2019cites this paper
• Bone marrow mesenchymal stem cells protect lungs from smoke inhalation injury by differentiating into alveolar epithelial cells via Notch signaling

  2019cites this paper
• Therapeutic host-directed strategies to improve outcome in tuberculosis

  2019cites this paper
• Precision medicine in the clinical management of respiratory tract infections including multidrug-resistant tuberculosis: learning from innovations in immuno-oncology

  2019cites this paper
• Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.

  2018cites this paper
• Mesenchymal stromal cells for treatment of the acute respiratory distress syndrome : The beginning of the

  2018cites this paper
• Perspectives for personalized therapy for patients with multidrug‐resistant tuberculosis

  2018cites this paper
• Clinical management of drug resistant Mycobacterium tuberculosis strains: Pathogen-targeted versus host-directed treatment approaches.

  2018cites this paper
• Pericytes in Veterinary Species: Prospective Isolation, Characterization and Tissue Regeneration Potential.

  2018cites this paper
• Remembering the Host in Tuberculosis Drug Development

  2018cites this paper
• The Troika Host–Pathogen–Extrinsic Factors in Tuberculosis: Modulating Inflammation and Clinical Outcomes

  2018cites this paper
• The use of immunotherapy for the treatment of tuberculosis

  2018cites this paper
• Landscape of Manufacturing Process of ATMP Cell Therapy Products for Unmet Clinical Needs

  2017cites this paper
• Stem cell therapy: an adjunct in the treatment of mdr tuberculosis

  2017cites this paper
• Mesenchymal stem cells internalize Mycobacterium tuberculosis through scavenger receptors and restrict bacterial growth through autophagy

  2017cites this paper
• Improving treatment outcomes for patients with pulmonary tuberculosis in Tanzania : host and pathogen factors

  2017cites this paper
• Host-Directed Therapeutic Strategies for Tuberculosis

  2017cites this paper
• The introduction of mesenchymal stromal cells induces different immunological responses in the lungs of healthy and M. tuberculosis infected mice

  2017cites this paper
• Host-directed therapies for bacterial and viral infections

  2017cites this paper
• Colapsoterapia con bolas de lucita

  2017cites this paper
• Mesenchymal stem cells of the bone marrow in treatment of genital tuberculosis in rabbits (experimental research with morphological control)

  2017cites this paper
• New drugs for the treatment of Mycobacterium tuberculosis infection.

  2017cites this paper
• Drug-Resistant Tuberculosis

  2017cites this paper
• Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis

  2017cites this paper
• A Novel Therapeutic Approach Using Mesenchymal Stem Cells to Protect Against Mycobacterium abscessus

  2016cites this paper
• Postprimary Tuberculosis and Macrophage Necrosis: Is There a Big ConNECtion?

  2016cites this paper
• Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis

  2016influential citation
• Emerging role of mesenchymal stem cells during tuberculosis: The fifth element in cell mediated immunity.

  2016cites this paper
• Immunotherapy for tuberculosis: future prospects

  2016cites this paper
• Personalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and Chronic Pulmonary Aspergillosis

  2016cites this paper
• BMI1 Regulation of Self-Renewal and Multipotency in Human Mesenchymal Stem Cells.

  2016cites this paper
• Efficacy and safety of a four-drug fixed-dose combination regimen versus separate drugs for treatment of pulmonary tuberculosis: a systematic review and meta-analysis

  2016cites this paper
• Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

  2016cites this paper
• Dynamic Tracking Human Mesenchymal Stem Cells Tropism following Smoke Inhalation Injury in NOD/SCID Mice

  2016cites this paper
• In Vivo Tracking of Systemically Administered Allogeneic Bone Marrow Mesenchymal Stem Cells in Normal Rats through Bioluminescence Imaging

  2016cites this paper
• Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis

  2016influential citation
• Cross-talk between the Immune System and Tuberculosis Pathogenesis; a Review with Emphasis on the Immune Based Treatment

  2016cites this paper
• Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

  2016cites this paper
• Directed Intervention and Immunomodulation against Pulmonary Tuberculosis

  2016cites this paper
• Host-directed therapies for antimicrobial resistant respiratory tract infections

  2016cites this paper
• Advancing host-directed therapy for tuberculosis

  2015cites this paper
• Adult stem cells in neural repair: Current options, limitations and perspectives.

  2015cites this paper
• The Influence of Oxygen on the Proliferative Capacity and Differentiation Potential of Lacrimal Gland-Derived Mesenchymal Stem Cells.

  2015cites this paper
• Inflammation and tuberculosis: host‐directed therapies

  2015cites this paper
• Host-directed therapies for tuberculous pericarditis.

  2015cites this paper
• Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32.

  2015cites this paper
• Corticosteroid therapy for pneumonia.

  2015cites this paper
• Update in Mycobacterium tuberculosis lung disease 2014.

  2015cites this paper
• Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.

  2015cites this paper
• Targeting Batf2 for infectious diseases and cancer

  2015cites this paper
• Towards tuberculosis elimination: an action framework for low-incidence countries

  2015cites this paper
• Mesenchymal Stromal Cell Therapy in MDR/XDR Tuberculosis: A Concise Review

  2015cites this paper